Pharnext Enrolls 1st Patient in PREMIER Trial Testing PXT3003 for CMT1A

Pharnext Enrolls 1st Patient in PREMIER Trial Testing PXT3003 for CMT1A

291348

Pharnext Enrolls 1st Patient in PREMIER Trial Testing PXT3003 for CMT1A

The first patient has been enrolled in a pivotal Phase 3 trial testing Pharnext’s investigational therapy PXT3003 for Charcot-Marie-Tooth disease type 1A (CMT1A), the company announced. Called PREMIER (NCT04762758), the trial intends to recruit approximately 350 patients, ranging in age from 16 to 65, with mild to moderate CMT1A — the most common disease type, accounting for about two-thirds of all cases. The trial is recruiting across 50 clinical sites in the U.S., Canada, Europe, and Israel. According to Pharnext,…

You must be logged in to read/download the full post.